{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078464","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.369662+00:00","generated_at":"2026-05-31T22:38:04.152900+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elanco completes sale of aqua business to Merck for ~$1.3B; debt reduction plan outlined","bullets":["Sale to Merck closed July 9 for ~$1.3B cash; net proceeds ~$1.05-1.1B for Q3 debt paydown.","Expected total debt paydown of ~$1.3-1.4B in 2024 from sale proceeds and base business cash flow.","Net debt to adjusted EBITDA target: mid-4x at 2024 year-end; improving to high-3x to low-4x in 2025.","Divestiture focuses Elanco on pet health and livestock; CFO cites three quarters of underlying revenue growth.","Additional financial outlook impact to be provided on Q2 2024 earnings call in August."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078464","json":"https://secwatch.observer/filing/0001104659-24-078464.json","markdown":"https://secwatch.observer/filing/0001104659-24-078464.md","text":"https://secwatch.observer/filing/0001104659-24-078464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924078464/0001104659-24-078464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924078464/tm2419092d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:38:04.152900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08521b3c4a3c8d29dc6c09ab77e6ec02a4665d45","claim":"Elanco Animal Health Inc completed a disposition involving Intervet International B.V. for approximately $1.3 billion in cash (closed 2024-07-09).","evidence_excerpt":"On July 9, 2024, Elanco, Buyer and their applicable affiliates consummated the Transaction. The purchase price was approximately $1.3 billion in cash, subject to customary post-closing adjustments set forth in the Purchase Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924078464/0001104659-24-078464-index.htm","confidence":0.98,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Intervet International B.V."},{"label":"Consideration","value":"approximately $1.3 billion in cash"},{"label":"Closing","value":"2024-07-09"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}